Corvus Pharmaceuticals

CRVS Small Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$14.69

+1.8% today

52W: $2.54 – $26.95

52W Low: $2.54 Position: 49.8% 52W High: $26.95

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

—

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$1.2B

Market Capitalization

Revenue Growth

—

YoY Revenue Growth

Profit Margin

—

Net profit margin

ROE

-32.6%

Return on Equity

Beta

0.97

Market sensitivity

Short Interest

23.48%

% of float sold short

Avg. Volume

3,441,029

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

None

6 analysts

Avg. Price Target

$35.17

+139.39% upside

Target Range

$27.00 – $51.00

About the Company

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; an

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 37 Exchange: NGM